XML 22 R11.htm IDEA: XBRL DOCUMENT

Significant Agreements	3 Months Ended
Mar. 31, 2026
Significant Agreements [Abstract]
Significant Agreements	Note 5 — Significant Agreements Immunovia AB On September 17, 2025, Proteomedix entered into a license agreement with Immunovia AB, pursuant to which Immunovia obtained exclusive rights to certain intellectual property and proprietary biological materials related to the PancreaSure™ test. In exchange for these rights, Immunovia paid Proteomedix a non-refundable upfront license fee of $0.3 million. Based on the terms of the agreement and the nature of the license, the Company determined that the performance obligations were satisfied upon the transfer of the licensed rights. Accordingly, the Company recognized the $0.6 million as license revenue during the year ended December 31, 2025. Additionally, the agreement provided for a second payment of $0.3 million due by March 31, 2026, which was received during the three months ended March 31, 2026, and is no longer shown as a part of Accounts receivable, net on the consolidated balance sheet as of March 31, 2026.

Significant Agreements

3 Months Ended

Mar. 31, 2026

Note 5 — Significant Agreements

Immunovia AB

On September 17, 2025, Proteomedix entered into a license agreement with Immunovia AB, pursuant to which Immunovia obtained exclusive rights to certain intellectual property and proprietary biological materials related to the PancreaSure™ test. In exchange for these rights, Immunovia paid Proteomedix a non-refundable upfront license fee of $0.3 million. Based on the terms of the agreement and the nature of the license, the Company determined that the performance obligations were satisfied upon the transfer of the licensed rights. Accordingly, the Company recognized the $0.6 million as license revenue during the year ended December 31, 2025. Additionally, the agreement provided for a second payment of $0.3 million due by March 31, 2026, which was received during the three months ended March 31, 2026, and is no longer shown as a part of Accounts receivable, net on the consolidated balance sheet as of March 31, 2026.